Category: Category 4

Fidelis Animal Health, Inc.  Nov 05, 2024 Ethiqa XR, an extended-release buprenorphine, adds captive rodents and laboratory rabbits to label for 72-hour control of post-procedural pain. NORTH BRUNSWICK, N.J., Nov. 5, 2024 /PRNewswire/ — Fidelis Animal Health, Inc. has received notification from the Food and Drug Administration (FDA) that Ethiqa XR (buprenorphine extended-release injectable suspension) 1.3 mg/mL is now indicated for the control of…